Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | CCR3 | P51677 | 2/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11062805 | 0.90 | SIGMAR1 (0.70) | OPRL1POLBSIGMAR1DRD2OPRM1 | |
| Hydrochloric Acid SCHEMBL11073893 | 0.89 | SIGMAR1 (0.68) | OPRL1POLBSIGMAR1DRD2OPRM1 | |
| SCHEMBL11684603 | 0.86 | OPRL1 (0.72) | OPRL1POLBSIGMAR1DRD2OPRM1 | |
| SCHEMBL24489451 | 0.83 | OPRL1 (0.65) | OPRL1POLBSIGMAR1DRD2OPRM1 | |
| SCHEMBL1307928 | 0.83 | OPRL1 (0.65) | OPRL1POLBSIGMAR1DRD2OPRM1 | |
| SCHEMBL8097585 | 0.81 | SIGMAR1 (0.82) | OPRL1POLBSIGMAR1DRD2CCR3 | |
| SCHEMBL9370237 | 0.81 | SIGMAR1 (0.72) | OPRL1POLBSIGMAR1DRD2CCR3 | |
| SCHEMBL1411499 | 0.81 | OPRL1 (1.00) | OPRL1POLBSIGMAR1OPRM1CCR3 | |
| SCHEMBL7233756 | 0.80 | SIGMAR1 (0.70) | OPRL1POLBSIGMAR1DRD2CCR3 | |
| SCHEMBL11778752 | 0.80 | SIGMAR1 (0.70) | OPRL1POLBSIGMAR1DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1942161-B | Compositions and treatments for demyelinating diseases and paralysis by administration of remyelinating drugs | ELAN PHARM INC | 2012-05-30 | — | — | CN | disclosed |
| US-7973044-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7968547-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7745454-B2 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7741328-B2 | Treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or Crohn's disease; Very Late Antigen-4 (VLA-4), also called alpha 4 beta 1 integrin; N-(sulfonamido-substituted pyrimidyl, pyridyl or pyrazyl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine compounds | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1144388-B1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARM INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7576101-B2 | Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-0994896-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006434-A1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006431-A1 | SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006436-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-4061760-A | Method for using 3-substituted-5-phenyl-5-pyridyl hydantoins as antiarrhythmic agents | MILES LABORATORIES, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-3994904-A | 3-Substituted -5-phenyl-5-pyridyl hydantoins | MILES LABORATORIES, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | OPRL1 612/4885POLB 4489/4885SIGMAR1 2667/4885 |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | OPRL1 612/4885POLB 4489/4885SIGMAR1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.